Holdings
Octagon Capital Advisors LP
As of Sep 30, 2026, Octagon Capital Advisors LP reported 24 positions worth US$732M. Largest: Dianthus Therapeutics, Inc., Abivax SA and Definium Therapeutics, Inc. What it bought and sold, with each filing.
Holdings
- Positions
- 24
- Value as reported
- US$732M
- Holdings as of
- Sep 30, 2026
- Last filed
- Nov 16, 2026
| Company | Shares | Value as reported | % of company | % of portfolio | Change | As of |
|---|---|---|---|---|---|---|
| Dianthus Therapeutics, Inc. NASDAQ:DNTH | 1.69M | US$149M | 19.8% | −155K | Sep 30, 2026 | |
| Abivax SA EURONEXT:ABVX | 993K | US$98.3M | 13.1% | no change | Sep 30, 2026 | |
| Definium Therapeutics, Inc. NASDAQ:DFTX | 2.51M | US$95.6M | 1.8% | 12.7% | −439K | Sep 30, 2026 |
| Cogent Biosciences, Inc. NASDAQ:COGT | 2.35M | US$75.2M | 10.0% | no change | Sep 30, 2026 | |
| ArriVent BioPharma, Inc. NASDAQ:AVBP | 2.14M | US$64.8M | 4.1% | 8.6% | +170K | Sep 30, 2026 |
| Taysha Gene Therapies, Inc. NASDAQ:TSHA | 9.69M | US$47.2M | 3.0% | 6.3% | no change | Sep 30, 2026 |
| Obsidian Therapeutics, Inc. NASDAQ:OBX | 2.41M | US$33.2M | 3.9% | 4.4% | new | Sep 30, 2026 |
| Kymera Therapeutics, Inc. NASDAQ:KYMR | 205K | US$22.9M | 3.1% | −105K | Sep 30, 2026 | |
| Disc Medicine, Inc. NASDAQ:IRON | 270K | US$17.7M | 0.59% | 2.4% | no change | Sep 30, 2026 |
| Tango Therapeutics, Inc. NASDAQ:TNGX | 630K | US$15.7M | 2.1% | new | Sep 30, 2026 | |
| Xenon Pharmaceuticals Inc. NASDAQ:XENE | 420K | US$15.6M | 2.1% | −70,000 | Sep 30, 2026 | |
| Adlai Nortye Group Ltd. NASDAQ:ANL | 935K | US$15M | 1.6% | 2.0% | new | Sep 30, 2026 |
| Mirum Pharmaceuticals, Inc. NASDAQ:MIRM | 169K | US$14.5M | 1.9% | −169K | Sep 30, 2026 | |
| Aktis Oncology, Inc. NASDAQ:AKTS | 713K | US$13.9M | 1.3% | 1.8% | −248K | Sep 30, 2026 |
| Palisade Bio, Inc. NASDAQ:PALI | 10.3M | US$13.9M | 5.7% | 1.8% | no change | Sep 30, 2026 |
| BioAge Labs, Inc. NASDAQ:BIOA | 1.3M | US$9.22M | 2.8% | 1.2% | −448K | Sep 30, 2026 |
| Gyre Therapeutics, Inc. NASDAQ:GYRE | 954K | US$7M | 0.83% | 0.93% | no change | Sep 30, 2026 |
| DBV Technologies SA EURONEXT:DBV | 574K | US$6.75M | 0.90% | no change | Sep 30, 2026 | |
| Ocular Therapeutix, Inc. NASDAQ:OCUL | 600K | US$4.6M | 0.27% | 0.61% | −1.48M | Sep 30, 2026 |
| Trevi Therapeutics, Inc. NASDAQ:TRVI | 315K | US$4.51M | 0.60% | no change | Sep 30, 2026 | |
| Sensei Biotherapeutics, Inc. NASDAQ:SNSE | 100K | US$2.97M | 0.39% | 0.40% | −261K | Sep 30, 2026 |
| Precision BioSciences, Inc. NASDAQ:DTIL | 430K | US$2.69M | 1.5% | 0.36% | −920K | Sep 30, 2026 |
| Unicycive Therapeutics, Inc. NASDAQ:UNCY | 275K | US$1.29M | 0.94% | 0.17% | −725K | Sep 30, 2026 |
| Gossamer Bio, Inc. NASDAQ:GOSS | 96,875 | US$1.15M | 1.6% | 0.15% | −7.65M | Sep 30, 2026 |